Clinical Trial Update: A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update concerns a sustained-release formulation of desvenlafaxine hydrochloride for the treatment of major depressive disorder, studied in P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Desvenlafaxine hydrochloride (sustained-release formulation) (Desvenlafaxine hydrochloride)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Major Depressive Disorder | Phase 2, Phase 3 | Status: UNKNOWN